Investment Bank Updates Price Target for Chugai Pharmaceutical
Investing.com – Japan stocks were higher after the close on Tuesday, as gains in the Marine Transport, Steel and Rubber sectors led shares higher. At the close in Tokyo, the...
PharmaMar (MC:PHMR) has capped off a strong performance in 2016 by signing a licence deal with Chugai (T:4519) for lurbinectedin (PM1183) in Japan, including €30m upfront and...
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.